PRQR — ProQR Therapeutics N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1612940 ·
Netherlands
Last close
$1.57
Market Cap
$221.56M
52W High
$3.10
52W Low
$1.33
ADV30
678,411
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 8,759,000 | — | -8,822,000 | -8,728,000 | 133,553,000 | 117,125,000 | 54,076,000 |
| Mar 2026 | 2,033,000 | — | -13,649,000 | -13,383,000 | 99,034,000 | 81,088,000 | 61,436,000 |
| Dec 2025 | 4,688,000 | — | -9,097,000 | -8,920,000 | 112,756,000 | 92,413,000 | 63,382,000 |
| Sep 2025 | 2,882,000 | — | -11,284,000 | -11,006,000 | 124,349,000 | 106,883,000 | 67,278,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-48,138,000
Investing CF
$-960,000
Financing CF
$-1,640,000
CapEx
$-960,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-478,894,000
Inventory
—
Receivables
$5,894,000
ST Investments
—
EBIT TTM
$-44,069,000
Pretax Income TTM
$-45,469,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,423,000
EBITDA
$-41,902,000
Free Cash Flow
$-19,073,124
Enterprise Value
$102,710,024
Total Cash
$117,125,000
Total Debt
$15,312,000
Shares Out
141,119,032
Trailing EPS
$-0.47
Book Value
$0.84
ROE
-57.4%
ROA
-19.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 15,906,000 | -43,446,000 | -42,184,000 | 112,756,000 | 63,382,000 | 49,374,000 | -52,791,000 |
| Dec 2024 | 18,905,000 | -30,472,000 | -27,763,000 | 167,958,000 | 79,398,000 | 88,560,000 | -36,393,000 |
| Dec 2023 | 6,514,000 | -34,790,000 | -28,119,000 | 137,883,000 | 96,493,000 | 41,390,000 | 21,548,000 |
| Dec 2022 | 3,594,000 | -65,159,000 | -64,424,000 | 171,321,000 | 104,640,000 | 67,065,000 | -68,508,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.47
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | $221.24M | $4.90 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $221.18M | $12.57 | — |
| GLSI | Greenwich LifeSciences, Inc. | $222.23M | $15.14 | — |
| IFRX | InflaRx N.V. | $225.47M | $1.53 | — |
| AKBA | Akebia Therapeutics, Inc. | $225.79M | $0.81 | — |
News headlines (Yahoo Finance, 1h cache)
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
2026-10-02 08:02 · Yahoo
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
2026-09-23 12:00 · Yahoo
ProQR to Participate in Upcoming Investor Conferences in September 2026
2026-09-02 12:00 · Yahoo
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
2026-06-25 10:35 · Yahoo
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
2026-06-25 10:25 · Yahoo
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
2026-05-14 12:25 · Yahoo
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
2026-05-11 12:00 · Yahoo
ProQR Announces First Quarter 2026 Operating and Financial Results
2026-05-12 11:00 · Yahoo
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
2026-05-04 12:00 · Yahoo
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
2026-04-30 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.